Peer-reviewedCC BY-NC-NDInternal Medicine
Characteristic Glycemic Patterns during Capivasertib Treatment Identified by Continuous Glucose Monitoring
Abstract
We herein report a case of hyperglycemia in a patient with recurrent breast cancer treated with the AKT inhibitor capivasertib. Continuous glucose monitoring revealed a distinctive pattern characterized by pronounced daytime postprandial hyperglycemia and nocturnal-to-morning decline, which resolved during the drug-free intervals. Hyperglycemia was unresponsive to metformin treatment but was markedly exacerbated by intravenous glucose infusion. These findings suggest that capivasertib-induced hyperglycemia is caused by an impaired glucose uptake and dysregulated hepatic glucose output associated with AKT inhibition. Careful glycemic monitoring and individualized management are necessary in patients receiving AKT inhibitors.
Related
- Early diagnosis of capivasertib-associated severe hyperglycemia with diabetic ketosis diagnosed in routine clinical practice: a case report with review of literature
- Microfluidic Profiling of an Immune Cell‐Associated Extracellular Vesicle Signature for Active Tuberculosis Diagnosis and Treatment Monitoring
- Self-aggregated photo-heterostructures enhancing fluorescence for cancer diagnosis and treatment monitoring
- Longitudinally Monitoring Prostate Cancer Bone Metastasis and Treatment Response via Circulating Extracellular Vesicles
- Plasma proteomic analysis identified potential therapeutic targets for pulmonary arterial hypertension
BibTeX
@article{takahashi2026characteristic,
title = {{Characteristic Glycemic Patterns during Capivasertib Treatment Identified by Continuous Glucose Monitoring}},
author = {Hironori Takahashi and Satoko Hatayama and Tomohito Izumi},
journal = {Internal Medicine},
year = {2026},
month = jul,
doi = {10.2169/internalmedicine.6353-25},
url = {https://www.jstage.jst.go.jp/article/internalmedicine/65/14/65_6353-25/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Characteristic Glycemic Patterns during Capivasertib Treatment Identified by Continuous Glucose Monitoring
AU - Hironori Takahashi
AU - Satoko Hatayama
AU - Tomohito Izumi
PY - 2026
DA - 2026/07/15
JO - Internal Medicine
DO - 10.2169/internalmedicine.6353-25
UR - https://www.jstage.jst.go.jp/article/internalmedicine/65/14/65_6353-25/_article
AB - We herein report a case of hyperglycemia in a patient with recurrent breast cancer treated with the AKT inhibitor capivasertib. Continuous glucose monitoring revealed a distinctive pattern characterized by pronounced daytime postprandial hyperglycemia and nocturnal-to-morning decline, which resolved during the drug-free intervals. Hyperglycemia was unresponsive to metformin treatment but was markedly exacerbated by intravenous glucose infusion. These findings suggest that capivasertib-induced hyperglycemia is caused by an impaired glucose uptake and dysregulated hepatic glucose output associated with AKT inhibition. Careful glycemic monitoring and individualized management are necessary in patients receiving AKT inhibitors.
SN - 1349-7235
SN - 0918-2918
ER -